CDLX Quote, Financials, Valuation and Earnings

Lendway has a net margin of -21.07% compared to Cardlytics's net margin of -16.97%. Cardlytics's return on equity of -138.45% beat Lendway's return on equity of -20.1%.

Cardlytics has a consensus price target of $3.30, signalling upside risk potential of 122.97%. On the other hand Lendway has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardlytics has higher upside potential than Lendway, analysts believe Cardlytics is more attractive than Lendway.

Cardlytics has a beta of 1.391, which suggesting that the stock is 39.101% more volatile than S&P 500. In comparison Lendway has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.468%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lendway offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Lendway pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $74M, which are larger than Lendway quarterly revenues of $6.6M. Cardlytics's net income of -$15.6M is lower than Lendway's net income of -$1.1M. Notably, Cardlytics's price-to-earnings ratio is -- while Lendway's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.26x versus 0.18x for Lendway. Usually stocks with elevated PS ratios are considered overvalued.

Magnite has a net margin of -21.07% compared to Cardlytics's net margin of 18.77%. Cardlytics's return on equity of -138.45% beat Magnite's return on equity of 3.16%.

Cardlytics has a consensus price target of $3.30, signalling upside risk potential of 122.97%. On the other hand Magnite has an analysts' consensus of $19.79 which suggests that it could grow by 104.46%. Given that Cardlytics has higher upside potential than Magnite, analysts believe Cardlytics is more attractive than Magnite.

Cardlytics has a beta of 1.391, which suggesting that the stock is 39.101% more volatile than S&P 500. In comparison Magnite has a beta of 2.660, suggesting its more volatile than the S&P 500 by 165.983%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Magnite offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Magnite pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $74M, which are smaller than Magnite quarterly revenues of $194M. Cardlytics's net income of -$15.6M is lower than Magnite's net income of $36.4M. Notably, Cardlytics's price-to-earnings ratio is -- while Magnite's PE ratio is 69.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.26x versus 2.15x for Magnite. Usually stocks with elevated PS ratios are considered overvalued.

Travelzoo has a net margin of -21.07% compared to Cardlytics's net margin of 15.56%. Cardlytics's return on equity of -138.45% beat Travelzoo's return on equity of 224.62%.

Cardlytics has a consensus price target of $3.30, signalling upside risk potential of 122.97%. On the other hand Travelzoo has an analysts' consensus of $25.25 which suggests that it could grow by 111.65%. Given that Cardlytics has higher upside potential than Travelzoo, analysts believe Cardlytics is more attractive than Travelzoo.

Cardlytics has a beta of 1.391, which suggesting that the stock is 39.101% more volatile than S&P 500. In comparison Travelzoo has a beta of 1.415, suggesting its more volatile than the S&P 500 by 41.464%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travelzoo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Travelzoo pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $74M, which are larger than Travelzoo quarterly revenues of $20.7M. Cardlytics's net income of -$15.6M is lower than Travelzoo's net income of $3.2M. Notably, Cardlytics's price-to-earnings ratio is -- while Travelzoo's PE ratio is 11.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.26x versus 1.82x for Travelzoo. Usually stocks with elevated PS ratios are considered overvalued.

Ziff Davis has a net margin of -21.07% compared to Cardlytics's net margin of 15.52%. Cardlytics's return on equity of -138.45% beat Ziff Davis's return on equity of 3.42%.

Cardlytics has a consensus price target of $3.30, signalling upside risk potential of 122.97%. On the other hand Ziff Davis has an analysts' consensus of $58.00 which suggests that it could grow by 82.62%. Given that Cardlytics has higher upside potential than Ziff Davis, analysts believe Cardlytics is more attractive than Ziff Davis.

Cardlytics has a beta of 1.391, which suggesting that the stock is 39.101% more volatile than S&P 500. In comparison Ziff Davis has a beta of 1.470, suggesting its more volatile than the S&P 500 by 46.994%.

Cardlytics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ziff Davis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardlytics pays -- of its earnings as a dividend. Ziff Davis pays out -- of its earnings as a dividend.

Cardlytics quarterly revenues are $74M, which are smaller than Ziff Davis quarterly revenues of $412.8M. Cardlytics's net income of -$15.6M is lower than Ziff Davis's net income of $64.1M. Notably, Cardlytics's price-to-earnings ratio is -- while Ziff Davis's PE ratio is 24.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardlytics is 0.26x versus 1.04x for Ziff Davis. Usually stocks with elevated PS ratios are considered overvalued.